Gliosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 30
Recruiting: 12
Ph III recruiting: 0
Growth YoY: —
Industry share: 3%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 43%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (55)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05095376	Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma	active not recruiting	Phase 3	265	NRG OncologyOTHER	2	Aug 17, 2026	clinicaltrials
NCT02152982	Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	active not recruiting	Phase 2 / Phase 3	447	National Cancer Institute (NCI)NIH	2	Jul 31, 2026